Narcan Now Available Over the Counter to Reverse Opioid Overdoses

Safety
Published

Narcan, the trade name for Naloxone HCl Nasal Spray, was approved for over-the-counter (OTC) nonprescription use by the U.S. Food and Drug Administration in March, becoming the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose.

Emergent BioSolutions has announced that shipments of its over the counter, original prescription strength NARCAN® Nasal Spray 4mg are now being delivered to leading pharmacies and grocery stores, as well as online retailers.

Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl. Construction workers account for nearly 23% of all opioid overdose deaths. Many of these happened on the job.

When someone is having an opioid overdose, the receptors in their brain get filled and overstimulated by opioids and when these receptors are full or are “maxed out,” your brain tells your body to slow down or even stop your breathing. Naloxone works to reverse this process. It works by binding with and blocking opioid receptors to rapidly reverse the effects of opioid overdose.

According to Emergent, last year, approximately every seven minutes one life was lost due to an opioid overdose, and today it is the leading cause of accidental death in the United States. The average response time for emergency services to arrive is approximately 10 minutes.

Having NARCAN® Nasal Spray in a first-aid kit on a job site, or carrying it on the go in case of an opioid emergency, can make a difference and help reverse the effects of opioids while waiting for emergency personnel to arrive.

The manufacturer’s suggested retail price of NARCAN® Nasal Spray is $44.99 per two-dose carton, roughly $22.50 per dose.

Learn more about Naloxone. NAHB also has resources to address the opioid crisis in construction.

Subscribe to NAHBNow

Log in or create account to subscribe to notifications of new posts.

Log in to subscribe

Latest from NAHBNow

Membership

Aug 05, 2026

Spring Membership Drive Rewards Strongest HBA Recruiters

Forty-eight home builders associations (HBAs) achieved tremendous recruitment and retention success in the 2026 Membership Drive program.

Advocacy

Aug 04, 2026

Podcast: 2 Key Lawmakers Explain Challenges in Passing Major Housing Bill

On the latest episode of NAHB’s podcast, Housing Developments, CEO Jim Tobin and COO Paul Lopez are joined by Reps. Mike Flood (R-Neb.) and Emanuel Cleaver (D-Mo.) to discuss the importance of the 21st Century ROAD to Housing Act and how they worked together to finalize this once-in-a-generation housing package.

View all

Latest Economic News

Economics

Aug 04, 2026

Construction Job Openings Rising

The number of open positions in the construction sector increased in June, per the Bureau of Labor Statistics Job Openings and Labor Turnover Survey (JOLTS). The current level of open jobs is down measurably from three years ago due to declines in construction activity, particularly in housing.

Economics

Aug 03, 2026

Residential Construction Spending Slips as Remodeling Activity Weakens

Private residential construction spending declined 0.3% in June, while substantial downward revisions to improvement (remodeling) spending significantly altered the sector’s recent trajectory.

Economics

Jul 31, 2026

Housing’s Share of GDP Moves Lower in the Second Quarter

Housing’s share of the economy was 15.8% in the second quarter of 2026, according to the latest estimates of GDP produced by the Bureau of Economic Analysis. This share is down from 15.9% in the first quarter and is at the lowest level since 2019.